Katharina Kreymborg, Ph.D.

Nina is a principal at Versant and brings more than 15 years of relevant scientific and business experience from previous operating roles, along with domain expertise in the fields of immunology and cancer immunotherapy. She most recently was VP and Head of Lead Discovery and External Innovation Research at MorphoSys. In that role, Nina was responsible for the identification and characterization of innovative antibody-based IO therapeutics, including the assessment of external assets and technologies. Before MorphoSys, Nina held roles of increasing responsibility within Roche’s Cancer Immunotherapy Division.